RE: .3 Jan 2021 18:30
Mr Star,
on 22nd oct GDR stated..
"The Company is targeting the end of the calendar year for completion of preliminary product evaluations, with full release of the final CE Marked system in Q1 2021 allowing for thorough clinical testing requirements."
In other words, the POC has hit delays as we've not heard about any evaluations (However, I'll give them the benefit of the doubt and allow them two weeks to publish an RNS containing the preliminary product evaluation ).
Unfortunately, all pi's would do well to remember that GDR is a company that publishes under financial highlights
"Financial Highlights
· Post year end, no material sales for 96 SARS-CoV-2 test as we await further registrations"
and ends the sentence with "advanced opportunity" in europe in 1Q21 .
First, this is not a financial highlight for 2020 however you may spin it
Second, it refers to potential not in 2020 but in 2021.
Third, this sentence tell us is how desperate GDR is to keep the sp as high as possible and please ii's who are making a mint dumping their shares onto pi's ..
GDR needs to produce some great RNS's this month, imo. I still believe they will. If the RNS's let the sp fall, I'll gladly sell and learn from my mistake.